CBD oil

Phase 3Small molecule

UUniversity Health Network, Toronto

CBD oil is one of 103 small molecule programs targeting Autism Spectrum Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autism Spectrum DisorderActive, not recruiting

Breast CancerActive, not recruiting

SclerodermaActive, not recruiting

Autism Spectrum DisorderPreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

SclerodermaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Tykerb

GSK

Preclinical

80 3

CBD oil

UUniversity Health Network, Toronto

Phase 3

1 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Avastin

BBio-Thera Solutions

Preclinical

153 6

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 7

Prolia

Amgen

Preclinical

14 8

Gemzar

GGynecologic Oncology Group

Preclinical

22 9

Voltaren

Novartis

Preclinical

1 10

Lupron

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Breast Cancer

NCT06787118

Clinical

Trials by Indication[1]

Scleroderma1 trial

Effectiveness of Cannabinoids on Appetite in Scleroderma

Completed·KKhon Kaen University·Phase 3·NCT05416697·30 enrolled

Autism Spectrum Disorder1 trial

SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)

Recruiting·NNeurothera Labs Inc.·N/A·NCT05182697·60 enrolled

Oral1 trial

Improving Pain Disability With the Use of Oral Cannabinoids

Completed·UUniversity Health Network, Toronto·N/A·NCT05351905·51 enrolled

Inflammation1 trial

Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV

Completed·UUniversity of Florida·Phase 4·NCT05209867·4 enrolled

Breast Cancer1 trial

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer

Not yet recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06787118·130 enrolled

1 more indication

Alcohol1 trial

Safety of Co-Administered CHI-554 and Alcohol

Completed·—·Phase 1·NCT05317507·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CBD oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBD oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBD oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Health Network, Toronto

CBD oil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Scleroderma1 trial

Autism Spectrum Disorder1 trial

Oral1 trial

Inflammation1 trial

Breast Cancer1 trial

Alcohol1 trial

References

Drug Info

Quick Facts

Related News